Here's Why Puma Biotechnology Fell 24.1% in July

Shares of Puma Biotechnology (NASDAQ: PBYI) continued their dismal year-to-date performance by slipping over 24% last month, according to data provided by S&P Global Market Intelligence. The pharma company didn't announce any company-specific news, but investors were eager to hedge their bets ahead of the second-quarter 2019 earnings release. That's understandable after seeing the first-quarter performance.